Search research articles
Contact Us
Filters
Showing results (231-240 of 244) with videos related to
Page
of 25
Sort By:
BMC Cancer
|
September 13, 2024
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
Qingyuan Zhang, Zhonghua Wang, Wei Yao, et al.
ACS Nano
|
December 21, 2016
Cross-Linked Fluorescent Supramolecular Nanoparticles as Finite Tattoo Pigments with Controllable Intradermal Retention Times
Jin-Sil Choi, Yazhen Zhu, Hongsheng Li, et al.
Frontiers in Oncology
|
December 24, 2021
TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
Hongling Liang, Jia Huang, Xiang Ao, et al.
American Journal of Ophthalmology
|
May 29, 2025
Explainable Deep Learning System for Automatic Detection of Thyroid Eye Disease Using Facial Images
Xiaodan Sui, Kenneth Ka Hei Lai, Richard Wai Chak Choy, et al.
NPJ Breast Cancer
|
February 10, 2025
Spatial proximity of CD8<sup>+</sup> T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer
Hongling Liang, Jianqing Huang, Hongsheng Li, et al.
British Journal of Cancer
|
June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
Wenjia Zuo, Zhonghua Wang, Jun Qian, et al.
The Journal of Clinical Investigation
|
August 29, 2017
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents
Minfeng Chen, Xueping Lei, Changzheng Shi, et al.
JAMA Oncology
|
March 19, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications
|
April 9, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications
|
May 9, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
Xichun Hu, Qingyuan Zhang, Tao Sun, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 244) with videos related to
Sort By:
Page
of 25
BMC Cancer
|
September 13, 2024
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
Qingyuan Zhang, Zhonghua Wang, Wei Yao, et al.
ACS Nano
|
December 21, 2016
Cross-Linked Fluorescent Supramolecular Nanoparticles as Finite Tattoo Pigments with Controllable Intradermal Retention Times
Jin-Sil Choi, Yazhen Zhu, Hongsheng Li, et al.
Frontiers in Oncology
|
December 24, 2021
TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
Hongling Liang, Jia Huang, Xiang Ao, et al.
American Journal of Ophthalmology
|
May 29, 2025
Explainable Deep Learning System for Automatic Detection of Thyroid Eye Disease Using Facial Images
Xiaodan Sui, Kenneth Ka Hei Lai, Richard Wai Chak Choy, et al.
NPJ Breast Cancer
|
February 10, 2025
Spatial proximity of CD8<sup>+</sup> T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer
Hongling Liang, Jianqing Huang, Hongsheng Li, et al.
British Journal of Cancer
|
June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
Wenjia Zuo, Zhonghua Wang, Jun Qian, et al.
The Journal of Clinical Investigation
|
August 29, 2017
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents
Minfeng Chen, Xueping Lei, Changzheng Shi, et al.
JAMA Oncology
|
March 19, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications
|
April 9, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications
|
May 9, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
Xichun Hu, Qingyuan Zhang, Tao Sun, et al.
Page
of 25